Details for New Drug Application (NDA): 050801
✉ Email this page to a colleague
The generic ingredient in EVOCLIN is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
Summary for 050801
| Tradename: | EVOCLIN |
| Applicant: | Norvium Bioscience |
| Ingredient: | clindamycin phosphate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | AEROSOL, FOAM;TOPICAL | Strength | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Oct 22, 2004 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 050801
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Norvium Bioscience | EVOCLIN | clindamycin phosphate | AEROSOL, FOAM;TOPICAL | 050801-001 | Oct 22, 2004 | 7,141,237 | ⤷ Get Started Free |
| Norvium Bioscience | EVOCLIN | clindamycin phosphate | AEROSOL, FOAM;TOPICAL | 050801-001 | Oct 22, 2004 | 7,374,747 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
